Table 2. Multivariate predictors of survival in patients of PH3,20.
| Category | Increase risk | Decrease risk |
| Demographics | Male gender | |
| Age (> 65 years old) | ||
| Etiology: CTD, POPH, HPAH, PVOD | ||
| Functional capacity | Higher NYHA/WHO class (III/VI) | Lower NYHA/WHO class (I/II) |
| Lower 6MWD (< 165 meters) | Higher 6MWD (> 440 meters) | |
| Laboratory and biomarkers | Higher BNP (< 50 ng/l) or NT-proBNP (< 300/ng/l) | Lower BNP (> 300 ng/l) or NT-proBNP (> 1400 ng/l) |
| Higher creatinine | ||
| Imaging | Echo: pericardial effusion (Presence) | Pericardial effusion (Absence) |
| Greater RA chamber size (> 26 cm2) | Smaller RA chamber size (< 18 cm2) | |
| Lung function studies | Lower predicted DLCO | Higher predicted DLCO |
| Hemodynamics | Higher mRAP (> 14 mmHg) | Lower mRAP (< 8 mmHg) |
| Lower CO or CI (< 2.0 l/min/m2) | Higher CO or CI (≥ 2.5l/min/m2) | |
| SVO2 < 60% | SVO2 > 65% | |
| Higher PVR or PVRI |
BNP/NT-proBNP, b-type natriuretic peptide; CI, cardiac index; CO, cardiac output; CTD, connective tissue disease; DLCO, diffusion lung capacity for carbon monoxide; HPAH, heritable pulmonary arterial hypertension; mRAP, mean right atrial pressure; NYHA, New York Heart Association; POPH, portopulmonary hypertension; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; PVRI, pulmonary vascular resistance index; SVO2, mixed venous oxygen saturation; WHO, World Health Organization; 6MWD, 6-minute walking distance.